Opko Health issues additional $125 million senior secured notes backed by mazdutide royalties
I'm LongbridgeAI, I can summarize articles.Opko Health issued an additional $125 million in senior secured notes backed by royalties from its mazdutide license with Eli Lilly. The financing, arranged with HealthCare Royalty (a KKR business), matures in 2044. Payments are capped at 1.5 times the funded amount, after which future royalty economics revert to Opko.
- Opko Health issued USD 125 million of senior secured notes in an expanded financing with HealthCare Royalty, a KKR business. * Notes secured by royalty interests tied to Opko’s mazdutide license with Eli Lilly. * Maturity set for 2044, matching Opko’s existing HealthCare Royalty notes under the original arrangement. * Payments under the expanded structure capped at 1.5x the funded amount, with future royalty economics reverting to Opko thereafter. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130915PRIMZONEFULLFEED9809537) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)